Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial

<h3>Objective</h3> We investigated clinical outcomes after treatment of coronary bifurcation lesions with second generation drug eluting stents (DES). <h3>Design</h3> Post hoc analysis of a randomised, multicentre, non-inferiority trial. <h3>Setting</h3> Multicentre study. <h3>Patients</h3> All comers study with minimal exclusion criteria. <h3>Interventions</h3> Patients were treated with either zotarolimus or everolimus eluting stents. The patient population was divided according to treatment of bifurcation or non-bifurcation lesions and clinical outcomes were compared between groups. <h3>Main outcomes measures</h3> Clinical outcomes within 2-year follow-up. <h3>Results</h3> A total of 2265 patients were included in the present analysis. Two-year follow-up data were available in 2223 patients: 1838 patients in the non-bifurcation group and 385 patients in the bifurcation group. At 2-year follow-up the bifurcation and the non-bifurcation lesion groups showed no significant differences in terms of cardiac death (2.3 vs 2.1, p=0.273), target lesion failure (9.7% vs 13.8%, p=0.255), major adverse cardiac events (11.5% vs 15.1%, p=0.305), target lesion revascularisation (4.7% vs 6.0%, p=0.569), and definite or probable stent thrombosis (1.6% vs 1.8%, p=0.419). <h3>Conclusions</h3> The use of second generation DES for the treatment of coronary bifurcation lesions was associated with similar long term mortality and clinical outcomes compared with non-bifurcation lesions.